Task: Answer Verification
Input (English): Question: Is hER2 amplification level a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment : a systematic review and meta-analysis?
Answer: HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based targeted therapy in the clinical adjuvant setting.
Output (English): no